MXPA04006113A - Derivados de triazoloquinolina utiles como ligandos receptores de adenosina. - Google Patents
Derivados de triazoloquinolina utiles como ligandos receptores de adenosina.Info
- Publication number
- MXPA04006113A MXPA04006113A MXPA04006113A MXPA04006113A MXPA04006113A MX PA04006113 A MXPA04006113 A MX PA04006113A MX PA04006113 A MXPA04006113 A MX PA04006113A MX PA04006113 A MXPA04006113 A MX PA04006113A MX PA04006113 A MXPA04006113 A MX PA04006113A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor ligands
- triazolo
- adenosine receptor
- derivatives useful
- solvates
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 2
- 102000009346 Adenosine receptors Human genes 0.000 title 1
- 108050000203 Adenosine receptors Proteins 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000012453 solvate Substances 0.000 abstract 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
Abstract
La presente invencion se refiere a ligandos de receptor de adenosina A3 de la formula general (I), dentro de aquellos antagonistas preferibles, asi como sus sales, solvatos e isomeros y las composiciones farmaceuticas que los contienen, al uso de los compuestos de la formula general (I), asi como sus sales, solvatos e isomeros, a la preparacion de los compuestos de la formula general (I) y sus sales, solvatos e isomeros, ademas a los intermediarios nuevos de la formula general (II) y a la preparacion de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0105407A HUP0105407A3 (en) | 2001-12-21 | 2001-12-21 | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
| PCT/HU2002/000143 WO2003053968A1 (en) | 2001-12-21 | 2002-12-17 | Triazolo-quinolin derivatives useful as adenosine receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04006113A true MXPA04006113A (es) | 2005-06-08 |
Family
ID=90001529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04006113A MXPA04006113A (es) | 2001-12-21 | 2002-12-17 | Derivados de triazoloquinolina utiles como ligandos receptores de adenosina. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7365089B2 (es) |
| EP (1) | EP1456204A1 (es) |
| JP (2) | JP4724366B2 (es) |
| KR (1) | KR100934796B1 (es) |
| CN (1) | CN1307175C (es) |
| AU (1) | AU2002353240B2 (es) |
| BR (1) | BR0215276A (es) |
| CA (1) | CA2470064C (es) |
| EA (1) | EA007066B1 (es) |
| HR (1) | HRP20040672A2 (es) |
| HU (2) | HUP0105407A3 (es) |
| IL (2) | IL162444A0 (es) |
| IS (1) | IS7318A (es) |
| MA (1) | MA27094A1 (es) |
| MX (1) | MXPA04006113A (es) |
| NO (1) | NO329757B1 (es) |
| NZ (1) | NZ534016A (es) |
| PL (1) | PL370747A1 (es) |
| RS (1) | RS56004A (es) |
| TN (1) | TNSN04106A1 (es) |
| UA (1) | UA79955C2 (es) |
| WO (1) | WO2003053968A1 (es) |
| ZA (1) | ZA200404802B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0105407A3 (en) * | 2001-12-21 | 2004-04-28 | Sanofi Aventis | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
| HUP0203976A3 (en) | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| HUP0400812A2 (en) * | 2004-04-19 | 2006-02-28 | Sanofi Aventis | Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them |
| MXPA06014637A (es) * | 2004-06-25 | 2007-02-12 | Amgen Inc | Triazoles e indazoles condensados utiles en el tratamiento de enfermedades mediadas por citocinas y otras enfermedades. |
| CN102702315A (zh) * | 2006-11-30 | 2012-10-03 | 首都医科大学 | 具有靶向抗血栓活性的rgdsyigsk、制备和应用 |
| CN102702313A (zh) * | 2006-11-30 | 2012-10-03 | 首都医科大学 | 具有靶向抗血栓活性的rgdvyigsr、制备和应用 |
| CN102702314A (zh) * | 2006-11-30 | 2012-10-03 | 首都医科大学 | 具有靶向抗血栓活性的rgdfyigsr、制备和应用 |
| CN102702316A (zh) * | 2006-11-30 | 2012-10-03 | 首都医科大学 | 具有靶向抗血栓活性的rgdfyigsk、制备和应用 |
| CN102702312A (zh) * | 2006-11-30 | 2012-10-03 | 首都医科大学 | 具有靶向抗血栓活性的rgdvyigsk、制备和应用 |
| HUP0700395A2 (en) * | 2007-06-07 | 2009-03-02 | Sanofi Aventis | Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates |
| DE102007061763A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
| CA2898018C (en) | 2013-02-01 | 2021-02-09 | Wellstat Therapeutics Corporation | Substituted quinolin-4-amine compounds and pharmaceutical compositions thereof having anti-inflammatory, antifungal, antiparasitic and anticancer activity |
| CN108358927B (zh) * | 2018-01-26 | 2020-09-01 | 郑州大学 | 1,4-二取代1,2,3-三氮唑核苷类似物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE280109C (es) | ||||
| DE280110C (es) | ||||
| GB1479759A (en) * | 1974-11-23 | 1977-07-13 | Lepetit Spa | Heterocyclic fused derivatives of indole and quinoline |
| DD280110A1 (de) * | 1989-02-22 | 1990-06-27 | Univ Berlin Humboldt | Verfahren zur herstellung von 1.2.4-triazolo/1.5-a/-pyridin-8-carbonitrilen |
| DD280109A1 (de) * | 1989-02-22 | 1990-06-27 | Univ Berlin Humboldt | Verfahren zur herstellung substituierter 1.2.4-triazolo/1.5-a/-pyridine |
| DE3926770A1 (de) | 1989-08-12 | 1991-02-14 | Basf Ag | (1,2,4)triazolo(1,5-a)pyridine |
| EP0885192B8 (en) * | 1996-01-29 | 2012-05-16 | The United States of America, Represented by the Secretary, Department of Health and Human Services | Dihydropyridine-, pyridine-, benzopyran- one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists |
| US5780481A (en) * | 1996-08-08 | 1998-07-14 | Merck & Co., Inc. | Method for inhibiting activation of the human A3 adenosine receptor to treat asthma |
| US6448253B1 (en) * | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
| US6355653B1 (en) * | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
| HUP0105407A3 (en) * | 2001-12-21 | 2004-04-28 | Sanofi Aventis | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
-
2001
- 2001-12-21 HU HU0105407A patent/HUP0105407A3/hu unknown
-
2002
- 2002-12-17 WO PCT/HU2002/000143 patent/WO2003053968A1/en active IP Right Grant
- 2002-12-17 AU AU2002353240A patent/AU2002353240B2/en not_active Ceased
- 2002-12-17 US US10/499,250 patent/US7365089B2/en not_active Expired - Fee Related
- 2002-12-17 CN CNB028256468A patent/CN1307175C/zh not_active Expired - Fee Related
- 2002-12-17 CA CA2470064A patent/CA2470064C/en not_active Expired - Fee Related
- 2002-12-17 UA UA20040706067A patent/UA79955C2/uk unknown
- 2002-12-17 BR BR0215276-2A patent/BR0215276A/pt not_active IP Right Cessation
- 2002-12-17 IL IL16244402A patent/IL162444A0/xx unknown
- 2002-12-17 EP EP02788260A patent/EP1456204A1/en not_active Withdrawn
- 2002-12-17 EA EA200400848A patent/EA007066B1/ru not_active IP Right Cessation
- 2002-12-17 HU HU0402282A patent/HUP0402282A3/hu unknown
- 2002-12-17 NZ NZ534016A patent/NZ534016A/en not_active IP Right Cessation
- 2002-12-17 KR KR1020047009789A patent/KR100934796B1/ko not_active IP Right Cessation
- 2002-12-17 PL PL02370747A patent/PL370747A1/xx not_active Application Discontinuation
- 2002-12-17 MX MXPA04006113A patent/MXPA04006113A/es active IP Right Grant
- 2002-12-17 RS YU56004A patent/RS56004A/sr unknown
- 2002-12-17 JP JP2003554684A patent/JP4724366B2/ja not_active Expired - Fee Related
-
2004
- 2004-06-07 MA MA27724A patent/MA27094A1/fr unknown
- 2004-06-08 TN TNP2004000106A patent/TNSN04106A1/en unknown
- 2004-06-10 IL IL162444A patent/IL162444A/en not_active IP Right Cessation
- 2004-06-16 IS IS7318A patent/IS7318A/is unknown
- 2004-06-17 ZA ZA200404802A patent/ZA200404802B/en unknown
- 2004-07-20 NO NO20043119A patent/NO329757B1/no not_active IP Right Cessation
- 2004-07-20 HR HR20040672A patent/HRP20040672A2/xx not_active Application Discontinuation
-
2008
- 2008-02-28 US US12/039,272 patent/US7713992B2/en not_active Expired - Fee Related
-
2010
- 2010-09-08 JP JP2010200550A patent/JP2011042653A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003246811A8 (en) | Terphenyl derivatives, preparation thereof, compositions containing same | |
| MXPA03004549A (es) | Derivados de 3-arilindola y su uso como agonistas del receptor cb2. | |
| MXPA02012033A (es) | Derivados de 2-aminocarbonil-9h-purina. | |
| SE0302760D0 (sv) | New compounds | |
| MXPA02009773A (es) | Derivados de indolin-2-ona y su uso como ligandos de receptores de ocitocina. | |
| ATE286500T1 (de) | 1,2,3,4-tetrahydroisochinolin-derivate | |
| MXPA03011244A (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6. | |
| SE0103836D0 (sv) | Novel compounds | |
| MY122392A (en) | Adamantane derivatives of use of p2x7 receptor antagonists, a process for their preparation, pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions | |
| BG106569A (en) | Purine derivatives | |
| BG104148A (en) | Indole and 2,3-dihydroindole derivatives, their preparation and use | |
| PL361361A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| BR0206595A (pt) | Composto, composição farmacêutica, e uso de um composto | |
| WO2005060959A8 (en) | Pyrazole derivatives and use thereof as orexin receptor antagonists | |
| MXPA04006113A (es) | Derivados de triazoloquinolina utiles como ligandos receptores de adenosina. | |
| PL361282A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| HK1070054A1 (en) | Arylsulfonyl derivatives with5-ht6 receptor affinity | |
| MA27501A1 (fr) | Derives d'imidazoquinoline en tant que ligands recepteurs de l'adenosine a3 | |
| MXPA04005313A (es) | Derivados de aminotetralin como antagonistas del receptor muscarinico. | |
| BG105847A (en) | Calcilytic compounds | |
| MXPA04006115A (es) | Derivados de imidazoquinolina. | |
| AR028743A1 (es) | DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA | |
| DE60201074D1 (en) | Pyrazolopyridinderivate | |
| MY129094A (en) | Condensed polycyclic compounds | |
| SE0004099D0 (sv) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| HC | Change of company name or juridical status |